HBK Sorce Advisory LLC reduced its stake in Boston Scientific Co. by 12.6% to 9,106 shares.
HBK Sorce Advisory LLC reduced its stake in Boston Scientific Co. (BSX) by 12.6%, now holding 9,106 shares valued at $701,000. Institutional investors own 89.07% of the company. Recent analyst ratings indicate a consensus "Moderate Buy" with an average price target of $85.38. Boston Scientific reported Q2 earnings of $0.62 per share and revenue of $4.12 billion, reflecting a 14.5% increase year-over-year. Insider trading was noted with EVP Wendy Carruthers selling shares.
September 15, 2024
5 Articles